会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • N-arylheteroarylalkyl imidazol-2-one compounds for treatment of arteriosclerosis
    • 用于治疗动脉硬化的N-芳基杂芳基烷基咪唑-2-酮化合物
    • US06492397B1
    • 2002-12-10
    • US09616639
    • 2000-07-26
    • David B. ReitzRobert E. Manning
    • David B. ReitzRobert E. Manning
    • A01N4330
    • C07D401/06C07D401/10C07D401/14
    • A class of N-arylheteroarylalkyl imidazol-2-one compounds is described for use in treatment of arteriosclerosis. Compounds of particular interest are angiotensin II antagonists of Formula I: wherein Ar is selected from wherein m is one; wherein R1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 4-methylbutyl, 2-ethylbutyl, n-pentyl, neopentyl, phenyl, methylphenyl, difluorophenyl, benzyl, phenethyl, cyclohexyl, cyclohexylmethyl, cyclohexylethyl, cyclohexanoyl, 1-oxo-2-cyclohexylethyl, benzoyl, 1-oxo-2-phenethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl and 2-hydroxybutyl; wherein R0 is hydrido; wherein R2 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclohexyl, cyclohexylmethyl, propylthio, butylthio, and hydroxyalkyl; wherein each of R3, R4, R6, R7, R8, R9, R10 and R11 is hydrido and R5 may be selected from COOH and tetrazolyl; or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
    • 描述了一类用于治疗动脉硬化的N-芳基杂芳基烷基咪唑-2-酮化合物。 特别感兴趣的化合物是式I的血管紧张素II拮抗剂:其中Ar选自其中m是1;其中R 1选自甲基,乙基,正丙基,异丙基,正丁基,仲丁基,异丁基,叔丁基, 4-甲基丁基,2-乙基丁基,正戊基,新戊基,苯基,甲基苯基,二氟苯基,苄基,苯乙基,环己基,环己基甲基,环己基乙基,环己酰基,1-氧代-2-环己基乙基,苯甲酰基,1-氧代-2-苯乙基, 1-氧代丙基,1-氧代丁基,1-氧代戊基和2-羟基丁基; 其中R 0是氢的; 其中R2选自甲基,乙基,正丙基,异丙基,正丁基,仲丁基,异丁基,叔丁基,正戊基,异戊基,新戊基,苯基,苄基,苯乙基,环己基,环己基甲基,丙硫基,丁硫基 ,和羟烷基; 其中R 3,R 4,R 6,R 7,R 8,R 9,R 10和R 11各自为氢,R 5可以选自COOH和四唑基; 或其互变异构体或其药学上可接受的盐。
    • 2. 发明授权
    • Use of N-arylheteroarylalkyl imidazol-2-one compounds for treatment of
circulatory disorders
    • 使用N-芳基杂芳基烷基咪唑-2-酮化合物治疗循环系统疾病
    • US5441970A
    • 1995-08-15
    • US107742
    • 1993-08-19
    • David B. ReitzRobert E. Manning
    • David B. ReitzRobert E. Manning
    • A61K31/4439C07D401/06C07D401/10C07D401/14A61K31/44
    • C07D401/06A61K31/4439C07D401/10C07D401/14
    • ##STR1## A class of N-arylheteroarylalkyl imidazol-2-one compounds is described for use in treatment of circulatory disorders such as hypertension and congestive heart failure. Compounds of particular interest are angiotensin II antagonists of formula (I) wherein A is selected from (a), (b), (c), (d), (e) and (f), wherein m is one; R
      1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 4-methylbutyl, 2-ethylbutyl, n-pentyl, neopentyl, phenyl, methylphenyl, difluorophenyl, benzyl, phenetyl, cyclohexyl, cyclohexylmethyl, cyclohexylethyl, cyclohexanoyl, 1-oxo-2-cyclohexylethyl, benzoyl, 1-oxo-2-phenethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl and 2-hydroxybutyl; wherein R
      0 is hydrido; wherein R
      2 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclohexyl, cyclohexylmethyl, propylthio, butylthio, and hydroxyalkyl; wherein each of R
      3 , R
      4 , R
      6 , R
      7 , R
      8 , R
      9 , R
      10 and R
      11 is hydrido and R
      5 must be seleted from COOH, SH, PO
      3 H
      2 , SO
      3 H, CONHNH
      2 , CONHNHSO
      2 CF
      3 , OH, (g), (h) and (i) wherein each of R
      42 and R
      43 is independently selected from chloro, cyano, nitro, trifluoromethyl, methoxycarbonyl and trifluoromethylsulfonyl; or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
    • PCT No.PCT / US92 / 02439 Sec。 371日期:1993年8月19日 102(e)日期1993年8月19日PCT提交1992年4月1日PCT公布。 第WO92 / 17469号公报 (i)(g)(h)(i)(a)(b)(c)< (f)(f)描述了一类N-芳基杂芳基烷基咪唑-2-酮化合物用于治疗循环系统疾病如高血压和充血性心力衰竭。 特别感兴趣的化合物是式(I)的血管紧张素II拮抗剂,其中A选自(a),(b),(c),(d),(e)和(f) R1选自甲基,乙基,正丙基,异丙基,正丁基,仲丁基,异丁基,叔丁基,4-甲基丁基,2-乙基丁基,正戊基,新戊基,苯基,甲基苯基,二氟苯基, 苯乙酰基,环己基,环己基甲基,环己基乙基,环己酰基,1-氧代-2-环己基乙基,苯甲酰基,1-氧代-2-苯乙基,1-氧代丙基,1-氧代丁基,1-氧代戊基和2-羟基丁基; 其中R 0是氢的; 其中R2选自甲基,乙基,正丙基,异丙基,正丁基,仲丁基,异丁基,叔丁基,正戊基,异戊基,新戊基,苯基,苄基,苯乙基,环己基,环己基甲基,丙基
    • 4. 发明授权
    • N-arylheteroarylalkyl imidazol-2-one compounds for treatment of
circulatory disorders
    • 用于治疗循环系统疾病的N-芳基杂芳基烷基咪唑-2-酮化合物
    • US5861420A
    • 1999-01-19
    • US784223
    • 1997-01-16
    • David B. ReitzRobert E. Manning
    • David B. ReitzRobert E. Manning
    • C07D401/06C07D401/10C07D401/14A01N43/40C07D401/00C07D413/00C07D417/04
    • C07D401/06C07D401/10C07D401/14
    • A class of N-arylheteroarylalkyl imidazol-2-one compounds is described for use in treatment of circulatory disorders such as hypertension and congestive heart failure. Compounds of particular interest are angiotensin II antagonists of the formula ##STR1## wherein A is selected from ##STR2## wherein m is one; wherein R.sup.1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 4-methylbutyl, 2-ethylbutyl, n-pentyl, neopentyl, phenyl, methylphenyl, difluorophenyl, benzyl, phenethyl, cyclohexyl, cyclohexylmethyl, cyclohexylethyl, cyclohexanoyl, 1-oxo-2-cyclohexylethyl, benzoyl, 1-oxo-2-phenethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl and 2-hydroxybutyl; wherein R.sup.0 is hydrido; wherein R.sup.2 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclohexyl, cyclohexylmethyl, propylthio, butylthio, and hydroxyalkyl; wherein each of R.sup.3, R.sup.4, R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.10 and R.sup.11 is hydrido and R.sup.5 must be selected from COOH, SH, P0.sub.3 H.sub.2, SO.sub.3 H, CONHNH.sub.2, CONHNHSO.sub.2 CF.sub.3, OH, ##STR3## wherein each of R.sup.42 and R.sup.43 is independently selected from chloro, cyano, nitro, trifluoromethyl, methoxycarbonyl and trifluoromethylsulfonyl; or a tautomer thereof or a pharmaceutically-aceptable salt thereof.
    • 描述了一类N-芳基杂芳基烷基咪唑-2-酮化合物用于治疗循环系统疾病如高血压和充血性心力衰竭。 特别感兴趣的化合物是下式的血管紧张素II拮抗剂:其中A选自 ,其中m是1; 其中R 1选自甲基,乙基,正丙基,异丙基,正丁基,仲丁基,异丁基,叔丁基,4-甲基丁基,2-乙基丁基,正戊基,新戊基,苯基,甲基苯基,二氟苯基, 苯乙基,环己基甲基,环己基乙基,环己酰基,1-氧代-2-环己基乙基,苯甲酰基,1-氧代-2-苯乙基,1-氧代丙基,1-氧代丁基,1-氧代戊基和2-羟基丁基; 其中R 0是氢的; 其中R2选自甲基,乙基,正丙基,异丙基,正丁基,仲丁基,异丁基,叔丁基,正戊基,异戊基,新戊基,苯基,苄基,苯乙基,环己基,环己基甲基,丙硫基,丁硫基 ,和羟烷基; 其中R 3,R 4,R 6,R 7,R 8,R 9,R 10和R 11各自为氢,R 5必须选自COOH,SH,PO 3 H 2,SO 3 H,CONHNH 2,CONHNHSO 2 CF 3,OH,
    • 5. 发明授权
    • N-substituted N-(.alpha.-triazolyl-toluyl)pyrrole compounds for
treatment of circulatory disorders
    • 用于治疗循环障碍的N-取代的N-(α-三唑基 - 甲苯酰基)吡咯化合物
    • US5484937A
    • 1996-01-16
    • US117269
    • 1993-09-07
    • Philippe R. BovyDavid B. ReitzRobert E. Manning
    • Philippe R. BovyDavid B. ReitzRobert E. Manning
    • C07D521/00C07D403/10A61K31/41
    • C07D231/12C07D233/56C07D249/08
    • A class of N-substituted N-(.alpha.-triazolyltoluyl)pyrrole compounds described for use in treatment of circulatory disorders. Compounds of particular interest are angiotensin II antagonists of the formula ##STR1## wherein m is one; wherein R.sup.1 is selected from alkyl; and wherein R.sup.2 is selected from alkyl; and wherein each of R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9 and R.sup.10 is independently selected from hydrido, halo, nitro, trifluoromethyl, hydroxy, alkoxy, cyano, carboxyl and methoxycarbonyl; with the proviso that at least one of R.sup.5 and R.sup.8 must be selected from COOH, SH, PO.sub.3 H.sub.2, SO.sub.3 H, CONHNH.sub.2, CONHNHSO.sub.2 CF.sub.3, OH, ##STR2## wherein each of R.sup.42 and R.sup.43 is independently selected from chloro, cyano, nitro, trifluoromethyl, methoxycarbonyl and trifluoromethylsulfonyl; or a tautomer thereof or a pharmaceutically-acceptable salt thereof. These compounds are particularly useful in treatment or control of hypertension and congestive heart failure.
    • 描述用于治疗循环系统疾病的一类N-取代的N-(α-三唑基甲苯磺酰基)吡咯化合物。 特别感兴趣的化合物是式IMAMA的血管紧张素II拮抗剂,其中m是1; 其中R1选自烷基; 并且其中R 2选自烷基; R 3,R 4,R 5,R 6,R 7,R 8,R 9和R 10各自独立地选自氢,卤素,硝基,三氟甲基,羟基,烷氧基,氰基,羧基和甲氧基羰基; 条件是R 5和R 8中的至少一个必须选自COOH,SH,PO3H2,SO3H,CONHNH2,CONHNHSO2CF3,OH,其中R42和R43各自独立地选自氯,氰基,硝基,三氟甲基, 甲氧基羰基和三氟甲基磺酰基; 或其互变异构体或其药学上可接受的盐。 这些化合物特别可用于治疗或控制高血压和充血性心力衰竭。
    • 7. 发明授权
    • N-arylheteroarylalkyl imidazol-2-one compounds for treatment of
circulatory disorders
    • 用于治疗循环障碍的N-亚油酸二甲基咪唑-2-酮化合物
    • US5164403A
    • 1992-11-17
    • US681011
    • 1991-04-05
    • David B. ReitzRobert E. Manning
    • David B. ReitzRobert E. Manning
    • A61K31/4439C07D401/06C07D401/10C07D401/14
    • C07D401/06A61K31/4439C07D401/10C07D401/14
    • A class of N-arylheteroarylalkyl imidazol-2-one compounds is described for use in treatment of circulatory disorders such as hypertension and congestive heart failure. Compounds of particular interest are angiotensin II antagonists of the formula ##STR1## wherein A is selected from ##STR2## wherein m is one; wherein R.sup.1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 4-methylbutyl, n-pentyl, neopentyl, phenyl, benzyl, phenethyl, cyclohexyl, cyclohexylmethyl, cyclohexylethyl, cyclohexanoyl, 1-oxo-2-cyclohexylethyl, benzoyl, 1-oxo-2-phenethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl and 2-hydroxybutyl; wherein R.sup.0 is selected from hydrido, methyl, fluoro, chloro, monofluoromethyl, difluoromethyl, trifluoromethyl, formyl, carboxyl and dimethoxymethyl; wherein R.sup.2 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclohexyl, cyclohexylmethyl, propylthio, butylthio, and hydroxyalkyl; wherein each of R.sup.3, R.sup.4, R.sup.6, R.sup.7, R.sup.8, R.sup.9, R.sup.10 and R.sup.11 is hydrido and R.sup.5 must be selected from COOH, SH, PO.sub.3 H.sub.2, SO.sub.3 H, CONHNH.sub.2, CONHNHSO.sub.2 CF.sub.3, OH, ##STR3## wherein each of R.sup.42 and R.sup.43 is independently selected from chloro, cyano, nitro, trifluoromethyl, methoxycarbonyl and trifluoromethylsulfonyl; or a tautomer thereof or a pharmaceutically-acceptable salt thereof.
    • 描述了一类N-芳基杂芳基烷基咪唑-2-酮化合物用于治疗循环系统疾病如高血压和充血性心力衰竭。 特别感兴趣的化合物是下式的血管紧张素II拮抗剂:其中A选自 其中m为1; 其中R1选自甲基,乙基,正丙基,异丙基,正丁基,仲丁基,异丁基,叔丁基,4-甲基丁基,正戊基,新戊基,苯基,苄基,苯乙基,环己基,环己基甲基,环己基乙基 ,环己酰基,1-氧代-2-环己基乙基,苯甲酰基,1-氧代-2-苯乙基,1-氧代丙基,1-氧代丁基,1-氧代戊基和2-羟基丁基; 其中R 0选自氢,甲基,氟,氯,单氟甲基,二氟甲基,三氟甲基,甲酰基,羧基和二甲氧基甲基; 其中R2选自甲基,乙基,正丙基,异丙基,正丁基,仲丁基,异丁基,叔丁基,正戊基,异戊基,新戊基,苯基,苄基,苯乙基,环己基,环己基甲基,丙硫基,丁硫基 ,和羟烷基; 其中R 3,R 4,R 6,R 7,R 8,R 9,R 10和R 11各自为氢,R 5必须选自COOH,SH,PO 3 H 2,SO 3 H,CONHNH 2,CONHNHSO 2 CF 3,OH,NNNHR 42和+ RE 其中R 42和R 43各自独立地选自氯,氰基,硝基,三氟甲基,甲氧基羰基和三氟甲基磺酰基; 或其互变异构体或其药学上可接受的盐。
    • 8. 发明授权
    • Renal-selective biphenylmethyl imidazole angiotensin II antagonists for
treatment of hypertension
    • 肾选择性联苯甲基咪唑血管紧张素II拮抗剂治疗高血压
    • US5302610A
    • 1994-04-12
    • US810321
    • 1991-12-19
    • Robert E. ManningDavid B. Reitz
    • Robert E. ManningDavid B. Reitz
    • A61K47/48C07D233/68C07D403/10A61K31/415A61K31/495C07D233/54C07D241/04C07D257/04C07D265/30
    • C07D403/10A61K47/48023A61K47/48061C07D233/68
    • Renal-selective compounds are described which, in one embodiment, are prodrugs preferentially converted in the kidney to compounds capable of blocking angiotensin II (AII) receptors. These prodrugs are conjugates formed from two components, namely, a first component provided by an AII antagonist compound and a second component which is capable of being cleaved from the first component when both components are chemically linked within the conjugate. The two components are chemically linked by a bond which is cleaved selectively in the kidney, for example, by an enzyme. The liberated AII antagonist compound is then available to block AII receptors within the kidney. Conjugates of particular interest are glutamyl derivatives of biphenylmethyl 1H-substituted imidazole compounds, of which N-acetyl-L-glutamic acid, 5-[[4'-[2-butyl-4-chloro-5-(hydroxymethyl)-1H-imidazol-1-ylmethyl][1,1'-biphenyl]-2-yl]carbonyl]hydrazide (shown below) is an example: ##STR1##
    • 描述了肾选择性化合物,其在一个实施方案中是优先在肾中转化为能够阻断血管紧张素II(AII)受体的化合物的前药。 这些前药是由两种组分形成的缀合物,即由AII拮抗剂化合物提供的第一组分和当两种组分在缀合物内化学连接时能够从第一组分切割的第二组分。 两种组分通过在肾脏中有选择性地切割的键化学连接,例如通过酶。 然后释放的AII拮抗剂化合物可用于阻断肾脏内的AII受体。 特别感兴趣的缀合物是联苯甲基1H-取代的咪唑化合物的谷氨酰基衍生物,其中N-乙酰基-L-谷氨酸5 - ((4' - (2-丁基-4-氯-5-(羟甲基) 咪唑-1-基甲基)(1,1'-联苯)-2-基)羰基)酰肼(如下所示)是一个实例:(*化学结构*)
    • 9. 发明授权
    • N-substituted N-(alpha-triazolyl-toluyl)pyrrole compounds and use for
treatment of circulatory disorders
    • N-取代的N-(ALPHA-TRIAZOLYL-TOLUYL)吡咯烷酮化合物和用于治疗循环障碍的用途
    • US5175180A
    • 1992-12-29
    • US630714
    • 1990-12-20
    • Philippe R. BovyDavid B. ReitzRobert E. Manning
    • Philippe R. BovyDavid B. ReitzRobert E. Manning
    • C07D403/10C07D403/14
    • C07D403/10C07D403/14
    • A class of N-substituted N-(.alpha.-triazolyltoluyl)pyrrole compounds described for use in treatment of circulatory disorders. Compounds of particular interest are angiotensin II antagonists of the formula ##STR1## wherein m is one; wherein R.sup.1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 4-methylbutyl, n-pentyl, neopentyl, phenyl, benzyl, phenethyl, cyclohexyl, cyclohexylmethyl, cyclohexylethyl, cyclohexanoyl, 1-oxo-2-cyclohexylethyl, benzoyl, 1-oxo-2-phenethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl and 2-hydroxybutyl; wherein R.sup.2 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclohexyl, cyclohexylmethyl, propylthio, butylthio, and hydroxyalkyl; wherein each of R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9 and R.sup.10 is independently selected from hydrido, halo, nitro, trifluoromethyl, hydroxy, alkoxy, cyano, carboxyl and methoxycarbonyl; with the proviso that at least one of R.sup.5 and R.sup.8 must be selected from COOH, SH, PO.sub.3 H.sub.2, SO.sub.3 H, CONHNH.sub.2, CONHNHSO.sub.2 CF.sub.3, OH, ##STR2## wherein each of R.sup.42 and R.sup.43 is independently selected from chloro, cyano, nitro, trifluoromethyl, methoxycarbonyl and trifluoromethylsulfonyl; or a tautomer thereof or a pharmaceutically-acceptable salt thereof. These compounds are particularly useful in treatment or control of hypertension and congestive heart failure.
    • 描述用于治疗循环系统疾病的一类N-取代的N-(α-三唑基甲苯磺酰基)吡咯化合物。 特别感兴趣的化合物是式IMAMA的血管紧张素II拮抗剂,其中m是1; 其中R1选自甲基,乙基,正丙基,异丙基,正丁基,仲丁基,异丁基,叔丁基,4-甲基丁基,正戊基,新戊基,苯基,苄基,苯乙基,环己基,环己基甲基,环己基乙基 ,环己酰基,1-氧代-2-环己基乙基,苯甲酰基,1-氧代-2-苯乙基,1-氧代丙基,1-氧代丁基,1-氧代戊基和2-羟基丁基; 其中R2选自甲基,乙基,正丙基,异丙基,正丁基,仲丁基,异丁基,叔丁基,正戊基,异戊基,新戊基,苯基,苄基,苯乙基,环己基,环己基甲基,丙硫基,丁硫基 ,和羟烷基; 其中R 3,R 4,R 5,R 6,R 7,R 8,R 9和R 10各自独立地选自氢,卤素,硝基,三氟甲基,羟基,烷氧基,氰基,羧基和甲氧基羰基; 条件是R 5和R 8中的至少一个必须选自COOH,SH,PO3H2,SO3H,CONHNH2,CONHNHSO2CF3,OH,其中R42和R43各自独立地选自氯,氰基,硝基,三氟甲基, 甲氧基羰基和三氟甲基磺酰基; 或其互变异构体或其药学上可接受的盐。 这些化合物特别可用于治疗或控制高血压和充血性心力衰竭。
    • 10. 发明授权
    • N-substituted imidazol-2-one compounds for treatment of circulatory
disorders
    • 用于治疗循环系统疾病的N-取代咪唑-2-酮化合物
    • US5087634A
    • 1992-02-11
    • US606806
    • 1990-10-31
    • David B. ReitzRobert E. Manning
    • David B. ReitzRobert E. Manning
    • C07D233/70C07D403/10C07D409/14
    • C07D403/10C07D233/70C07D409/14
    • A class of N-substituted imidazol-2-one compounds is described for use in treatment of circulatory disorders. Compounds of particular interest are angiotensin II antagonists of the formula ##STR1## wherein m is one; wherein R.sup.1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 4-methylbutyl, n-pentyl, neopentyl, phenyl, benzyl, phenethyl, cyclohexyl, cyclohexylmethyl, cyclohexylethyl, cyclohexanoyl, 1-oxo-2-cyclohexylethyl, benzoyl, 1-oxo-2-phenethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl and 2-hydroxybutyl; wherein R.sup.0 is selected from hydrido, methyl, fluoro, chloro, monofluoromethyl, difluoromethyl, trifluoromethyl, formyl, carboxyl and dimethoxymethyl; wherein R.sup.2 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, phenyl, benzyl, phenethyl, cyclohexyl, cyclohexylmethyl, propylthio, butylthio, and hydroxyalkyl; wherein each of R.sup.3, R.sup.4, R.sup.6, R.sub.7, R.sup.8, R.sup.10 and R.sup.11 is hydrido; with the proviso that at least one of R.sup.5 and R.sup.9 must be selected from COOH, SH, PO.sub.3 H.sub.2, SO.sub.3 H, CONHNH.sub.2, CONHNHSO.sub.2 CF.sub.3, OH, ##STR2## wherein each of R.sup.42 and R.sup.43 is independently selected from chloro, cyano, nitro, trifluoromethyl, methoxycarbonyl and trifluoromethylsulfonyl; or a tautomer thereof or a pharmaceutically-acceptable salt thereof. These compounds are particularly useful in treatment or control of hypertension and congestive heart failure.
    • 描述了一类用于治疗循环障碍的N-取代咪唑-2-酮化合物。 特别感兴趣的化合物是式IMAMA的血管紧张素II拮抗剂,其中m是1; 其中R1选自甲基,乙基,正丙基,异丙基,正丁基,仲丁基,异丁基,叔丁基,4-甲基丁基,正戊基,新戊基,苯基,苄基,苯乙基,环己基,环己基甲基,环己基乙基 ,环己酰基,1-氧代-2-环己基乙基,苯甲酰基,1-氧代-2-苯乙基,1-氧代丙基,1-氧代丁基,1-氧代戊基和2-羟基丁基; 其中R 0选自氢,甲基,氟,氯,单氟甲基,二氟甲基,三氟甲基,甲酰基,羧基和二甲氧基甲基; 其中R2选自甲基,乙基,正丙基,异丙基,正丁基,仲丁基,异丁基,叔丁基,正戊基,异戊基,新戊基,苯基,苄基,苯乙基,环己基,环己基甲基,丙硫基,丁硫基 ,和羟烷基; 其中R3,R4,R6,R7,R8,R10和R11各自为氢; 条件是R 5和R 9中的至少一个必须选自COOH,SH,PO 3 H 2,SO 3 H,CONHNH 2,CONHNHSO 2 CF 3,OH,其中R 42和R 43各自独立地选自氯, 氰基,硝基,三氟甲基,甲氧基羰基和三氟甲基磺酰基; 或其互变异构体或其药学上可接受的盐。 这些化合物特别可用于治疗或控制高血压和充血性心力衰竭。